HH&L Acquisition Co. Redeemable
HHLA-WT
New York Stock Exchange0.00
USD
-0.01
- -
CIK
0001824185
Return %
Stock
S&P500
1Y
-92.38
18.21
3Y
-92.38
64.38
5Y
-92.38
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001824185
- Similar Companies
- Business
- HH&L Acquisition Co. Redeemable is a special purpose acquisition company (SPAC) primarily focused on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more healthcare or healthcare-related companies. The company targets businesses mainly in Asian markets, especially the Greater China region, or global healthcare companies with significant growth potential in these markets. HH&L Acquisition Co. offers units consisting of Class A ordinary shares and redeemable warrants, each warrant exercisable for one Class A ordinary share at a set exercise price. The company was incorporated in 2020 and is headquartered in Central, Hong Kong. The primary business activities of HH&L Acquisition Co. involve seeking and completing business combinations in the healthcare sector, focusing on creating long-term shareholder value through strategic acquisitions. Its services include facilitating capital market access for target companies through its SPAC structure, involving IPO units, shares, and warrants trading primarily on the New York Stock Exchange. The company’s product offerings include capital market instruments such as ordinary shares and redeemable warrants that support the acquisition strategy. A major recent development includes the completion of a significant initial public offering raising over $400 million to fund acquisitions and business combinations. In October 2022, HH&L Acquisition Co. entered into a definitive agreement to be acquired by DiaCarta Inc., a biotechnology company, representing a strategic merger aligning with its healthcare focus. The company announced a complete share redemption and liquidation process in early 2024, signaling operational and structural shifts post-business combination. HH&L Acquisition Co. has also undergone strategic shifts by extending its business combination periods and adjusting shareholder redemption rights as part of its organizational management and investment exit strategies. Operating within the financial services and healthcare investment industry segments, HH&L Acquisition Co. serves institutional investors and healthcare enterprises seeking growth and expansion in Asian and global markets. It maintains its base in Hong Kong while engaging in financial and capital markets activities principally in the US and Greater China regions. The company also maintains underwriter relationships with major financial institutions such as Goldman Sachs (Asia) and Credit Suisse Securities for its public offerings and capital market transactions.